title: When to consider a diagnosis of MODY at the presentation of diabetes: aetiology matters for correct management.
authors.affiliation: Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford.
authors.forename: Agata
authors.initials: A
authors.lastname: Juszczak
authors.affiliation: The Swan Practice, Buckingham.
authors.forename: Rebecca
authors.initials: R
authors.lastname: Pryse
authors.affiliation: 19 Beaumont St Surgery, Oxford.
authors.forename: Andrew
authors.initials: A
authors.lastname: Schuman
authors.affiliation: Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford; Oxford National Institute for Health Research (NIHR) Biomedical Centre, Churchill Hospital, Oxford.
authors.forename: Katharine R
authors.initials: KR
authors.lastname: Owen
mesh_terms: D000328:Adult; D017668:Age of Onset; D003924:Diabetes Mellitus, Type 2 / Q000175:diagnosis* / Q000235:genetics / Q000628:therapy; D003937:Diagnosis, Differential; D005260:Female; D058006:General Practice; D005820:Genetic Testing; D005907:Gliclazide / Q000627:therapeutic use*; D005941:Glucokinase / Q000235:genetics*; D051538:Hepatocyte Nuclear Factor 1-alpha / Q000235:genetics*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008297:Male; D009154:Mutation; D017410:Practice Guidelines as Topic; D040242:Risk Reduction Behavior; D013577:Syndrome
chemical_list: C496487:HNF1A protein, human; D051538:Hepatocyte Nuclear Factor 1-alpha; D007004:Hypoglycemic Agents; D005941:Glucokinase; D005907:Gliclazide